Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Editing

James Wilson’s Passage Bio raises $110 million

by Ryan Cross
September 14, 2019 | A version of this story appeared in Volume 97, Issue 36

Passage Bio, a gene therapy start-up cofounded by University of Pennsylvania scientist James Wilson (see page 32), has raised $110 million in series B financing from over 10 venture capital firms. Passage focuses on rare genetic neurological diseases. It will use the money to begin testing therapies for GM1 gangliosidosis and frontotemporal dementia in the first half of 2020, along with a therapy for Krabbe disease in the second half. Passage also plans clinical trials in 2021 for Charcot-Marie-Tooth neuropathy and two other unnamed diseases, and it has the option to license gene therapies from Wilson’s lab for 6 additional diseases. Catalent recently agreed to build a viral gene therapy manufacturing suite for Passage.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.